John Gordon

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

John Gordon
May 23, 2025, 11:16 | Blog
John Gordon: SERT as a Novel Target in Cancer Immunotherapy via SSRIs
John Gordon, Co-Founder, Director and VP of Scientific Affairs at Celentyx, shared a post on LinkedIn:…
Feb 22, 2025, 15:04 | Blog
John Gordon: Successful CAR Tcell Therapy - "It's a Bug's Life"
John Gordon, Co-Founder, Director and VP of Scientific Affairs at Celentyx, posted on LinkedIn about…
Feb 7, 2025, 08:57 | Science
John Gordon: Researchers identified a substantial presence of peripherally induced Treg cells in TME
John Gordon, Co-Founder, Director and VP of Scientific Affairs at Celentyx, shared a post on…
Feb 3, 2025, 11:59 | Science
James Crowley: The identification of tumor-specific targets in expanding immunotherapy development
James Crowley, Professor of Medicine Emeritus at Brown University, shared a post on LinkedIn by…
Jan 3, 2025, 12:51 | Science
Targeting Molecular Pathways to Control ICI Toxicities
John Gordon, VP Scientific Affairs, Co-Founder and Director at Celentyx Ltd, shared an article by…
Dec 30, 2024, 13:35 | Insight
James Crowley: Elevated expression of CCR7 is generally indicative of poor prognosis in cancers
James Crowley, Professor of Medicine Emeritus at Brown University, shared a post on LinkedIn by…
Nov 6, 2024, 12:01 | Insight
John Gordon: Dual “ON/OFF”-switch CARs offer a safer CAR T cell therapy
John Gordon, Vice president of Scientific Affairs at Celentyx Ltd, shared a post on LinkedIn: “Dual ‘ON/OFF’-switch CARs…
Apr 21, 2024, 23:39 | Insight
John Gordon: CART cells vs B cells Deliver a 'Killer Punch' to CAR-ve Onlookers 
John Gordon, Vice president of Scientific Affairs at Celentyx Ltd, shared a post on LinkedIn: "CART…
Feb 19, 2024, 14:39 | Opinion
John Gordon: The immune landscape of more than 1,000 tumors across ten different cancers using CPTAC pan-cancer proteogenomic data
John Gordon, VP Scientific Affairs, Co-Founder, Director at Celentyx Ltd shared the following on LinkedIn:…
All: 9 Posts: 1 - 100
Special Coverage